Correlation of CCL20 expression in rectal mucosa with the development of ulcerative colitis‑associated neoplasia

Hashimoto,Kiyoshi; Saigusa,Susumu; Araki,Toshimitsu; Tanaka,Koji; Okita,Yoshiki; Fujikawa,Hiroyuki; Kawamura,Mikio; Okugawa,Yoshinaga; Toiyama,Yuji; Inoue,Yasuhiro; Uchida,Keiichi; Mohri,Yasuhiko; Kusunoki,Masato

doi:10.3892/ol.2013.1528

Correlation of CCL20 expression in rectal mucosa with the development of ulcerative colitis‑associated neoplasia

Authors:
- Kiyoshi Hashimoto
- Susumu Saigusa
- Toshimitsu Araki
- Koji Tanaka
- Yoshiki Okita
- Hiroyuki Fujikawa
- Mikio Kawamura
- Yoshinaga Okugawa
- Yuji Toiyama
- Yasuhiro Inoue
- Keiichi Uchida
- Yasuhiko Mohri
- Masato Kusunoki
View Affiliations

Affiliations: Department of Gastrointestinal and Pediatric Surgery, Division of Reparative Medicine, Institute of Life Sciences, Mie University Graduate School of Medicine, Tsu, Mie 514‑8507, Japan
Published online on: August 16, 2013 https://doi.org/10.3892/ol.2013.1528
Pages: 1271-1276

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Chronic inflammation increases the risk of developing several gastrointestinal malignancies. Chemokines that are produced by colonic epithelial cells play significant roles in the maintenance and repair of the epithelial barrier. The present study aimed to clarify whether the expression of CCL20 and its receptor, CCR6, was correlated with the development of ulcerative colitis (UC)‑associated neoplasia. A total of 93 patients with UC who underwent proctocolectomies were enrolled in the present study. Immunohistochemical analysis for CCL20 and CCR6 expression in the rectal mucosa was performed and the correlation between expression and the pathogenesis of UC‑associated neoplasia was investigated. A total of 16 (17.2%) patients presented with UC‑associated neoplasia. The immunohistochemistry (IHC) score for CCL20 was significantly increased in the patients with a mild form of the disease (P=0.0363). The IHC score for CCL20 expression in the patients with UC‑associated neoplasia was higher compared with the patients without neoplasia (P=0.0294). In contrast, there was no significant correlation between CCR6 expression and the clinicopathological variables. The logistic regression analysis revealed that a high IHC score for CCL20 expression in the rectal mucosa and a disease duration of more than eight years were significantly correlated with the development of UC‑associated neoplasia (P<0.05). The results suggest that an evaluation of CCL20 expression in the rectal mucosa may be useful to identify patients who are at a high risk for developing UC‑associated neoplasia. However, a selection bias existed in the present study due to the fact that the patient population that was enrolled was not representative of a typical surveillance patient population.

View Figures

View References

1	Danese S and Fiocchi C: Ulcerative colitis. N Engl J Med. 365:1713–1725. 2011. View Article : Google Scholar : PubMed/NCBI
2	Eaden JA, Abrams KR and Mayberry JF: The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 48:526–535. 2001. View Article : Google Scholar : PubMed/NCBI
3	Cho JH and Brant SR: Recent insights into the genetics of inflammatory bowel disease. Gastroenterology. 140:1704–1712. 2011. View Article : Google Scholar : PubMed/NCBI
4	Thompson AI and Lees CW: Genetics of ulcerative colitis. Inflamm Bowel Dis. 17:831–848. 2011. View Article : Google Scholar : PubMed/NCBI
5	Slaughter DP, Southwick HW and Smejkal W: Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer. 6:963–968. 1953. View Article : Google Scholar : PubMed/NCBI
6	Chai H and Brown RE: Field effect in cancer-an update. Ann Clin Lab Sci. 39:331–337. 2009.PubMed/NCBI
7	Zimmerman NP, Vongsa RA, Wendt MK and Dwinell MB: Chemokines and chemokine receptors in mucosal homeostasis at the intestinal epithelial barrier in inflammatory bowel disease. Inflamm Bowel Dis. 14:1000–1011. 2008. View Article : Google Scholar : PubMed/NCBI
8	Koelink PJ, Overbeek SA, Braber S, et al: Targeting chemokine receptors in chronic inflammatory diseases: an extensive review. Pharmacol Ther. 133:1–18. 2012. View Article : Google Scholar : PubMed/NCBI
9	Williams IR: CCR6 and CCL20: partners in intestinal immunity and lymphorganogenesis. Ann NY Acad Sci. 1072:52–61. 2006. View Article : Google Scholar : PubMed/NCBI
10	Izadpanah A, Dwinell MB, Eckmann L, et al: Regulated MIP-3alpha/CCL20 production by human intestinal epithelium: mechanism for modulating mucosal immunity. Am J Physiol Gastrointest Liver Physiol. 280:G710–G719. 2001.PubMed/NCBI
11	Kwon JH, Keates S, Bassani L, et al: Colonic epithelial cells are a major site of macrophage inflammatory protein 3alpha (MIP-3alpha) production in normal colon and inflammatory bowel disease. Gut. 51:818–826. 2002. View Article : Google Scholar
12	Kaser A, Ludwiczek O, Holzmann S, et al: Increased expression of CCL20 in human inflammatory bowel disease. J Clin Immunol. 24:74–85. 2004. View Article : Google Scholar : PubMed/NCBI
13	Katchar K, Kelly CP, Keates S, et al: MIP-3alpha neutralizing monoclonal antibody protects against TNBS-induced colonic injury and inflammation in mice. Am J Physiol Gastrointest Liver Physiol. 292:G1263–G1271. 2007. View Article : Google Scholar : PubMed/NCBI
14	Cook DN, Prosser DM, Forster R, et al: CCR6 mediates dendritic cell localization, lymphocyte homeostasis, and immune responses in mucosal tissue. Immunity. 12:495–503. 2000. View Article : Google Scholar : PubMed/NCBI
15	Varona R, Cadenas V, Flores J, et al: CCR6 has a non-redundant role in the development of inflammatory bowel disease. Eur J Immunol. 33:2937–2946. 2003. View Article : Google Scholar : PubMed/NCBI
16	Wong SC, Lo SF, Lee KC, et al: Expression of frizzled-related protein and Wnt-signalling molecules in invasive human breast tumours. J Pathol. 196:145–153. 2002. View Article : Google Scholar : PubMed/NCBI
17	Itzkowitz SH and Present DH; Crohn’s and Colitis Foundation of America Colon Cancer in IBD Study Group. Consensus conference: Colorectal cancer screening and surveillance in inflammatory bowel disease. Inflamm Bowel Dis. 11:314–321. 2005. View Article : Google Scholar : PubMed/NCBI
18	Eaden JA and Mayberry JF; British Society for Gastroenterology; Association of Coloproctology for Great Britain and Ireland. Guidelines for screening and surveillance of asymptomatic colorectal cancer in patients with inflammatory bowel disease. Gut. 51(Suppl 5): V10–V12. 2002. View Article : Google Scholar : PubMed/NCBI
19	Ullman T, Odze R and Farraye FA: Diagnosis and management of dysplasia in patients with ulcerative colitis and Crohn’s disease of the colon. Inflamm Bowel Dis. 15:630–638. 2009.
20	Velayos FS, Liu L, Lewis JD, et al: Prevalence of colorectal cancer surveillance for ulcerative colitis in an integrated health care delivery system. Gastroenterology. 139:1511–1518. 2010. View Article : Google Scholar : PubMed/NCBI
21	Chen R, Rabinovitch PS, Crispin DA, et al: DNA fingerprinting abnormalities can distinguish ulcerative colitis patients with dysplasia and cancer from those who are dysplasia/cancer-free. Am J Pathol. 162:665–672. 2003. View Article : Google Scholar
22	Neumann H, Vieth M, Langner C, et al: Cancer risk in IBD: how to diagnose and how to manage DALM and ALM. World J Gastroenterol. 17:3184–3191. 2011.PubMed/NCBI
23	Matsumoto T, Kudo T, Jo Y, et al: Magnifying colonoscopy with narrow band imaging system for the diagnosis of dysplasia in ulcerative colitis: a pilot study. Gastrointest Endosc. 66:957–965. 2007. View Article : Google Scholar : PubMed/NCBI
24	Neumann H, Kiesslich R, Wallace MB and Neurath MF: Confocal laser endomicroscopy: technical advances and clinical applications. Gastroenterology. 139:388–392. 2010. View Article : Google Scholar : PubMed/NCBI
25	Kiesslich R: Chromoendoscopy: what is its true value for ulcerative colitis surveillance? Dig Dis. 28:445–451. 2010. View Article : Google Scholar : PubMed/NCBI
26	Bista RK, Brentnall TA, Bronner MP, et al: Using optical markers of nondysplastic rectal epithelial cells to identify patients with ulcerative colitis-associated neoplasia. Inflamm Bowel Dis. 17:2427–2435. 2011. View Article : Google Scholar
27	Ghadjar P, Rubie C, Aebersold DM and Keilholz U: The chemokine CCL20 and its receptor CCR6 in human malignancy with focus on colorectal cancer. Int J Cancer. 125:741–745. 2009. View Article : Google Scholar : PubMed/NCBI
28	Brand S, Olszak T, Beigel F, et al: Cell differentiation dependent expressed CCR6 mediates ERK-1/2, SAPK/JNK, and Akt signaling resulting in proliferation and migration of colorectal cancer cells. J Cell Biochem. 97:709–723. 2006. View Article : Google Scholar : PubMed/NCBI
29	Rubie C, Oliveira V, Kempf K, et al: Involvement of chemokine receptor CCR6 in colorectal cancer metastasis. Tumour Biol. 27:166–174. 2006. View Article : Google Scholar : PubMed/NCBI
30	Connell WR, Talbot IC, Harpaz N, et al: Clinicopathological characteristics of colorectal carcinoma complicating ulcerative colitis. Gut. 35:1419–1423. 1994. View Article : Google Scholar
31	Hinton JM: Risk of malignant change in ulcerative colitis. Gut. 7:427–432. 1966. View Article : Google Scholar : PubMed/NCBI
32	Lavery IC, Chiulli RA, Jagelman DG, et al: Survival with carcinoma arising in mucosal ulcerative colitis. Ann Surg. 195:508–512. 1982. View Article : Google Scholar : PubMed/NCBI
33	Mikami T, Yoshida T, Numata Y, et al: Invasive behavior of ulcerative colitis-associated carcinoma is related to reduced expression of CD44 extracellular domain: comparison with sporadic colon carcinoma. Diagn Pathol. 6:302011. View Article : Google Scholar